Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Blood. 2013 Aug 1;122(5):734-7. doi: 10.1182/blood-2013-04-495341. Epub 2013 Jun 25.
We evaluated long-term outcomes of 60 patients with chronic lymphocytic leukemia treated with an initial therapy of lenalidomide. At a median follow-up of 4 years, time-to-treatment failure has not been reached and overall survival is 82%. Thirty-five (58%) patients had a response lasting >36 months (long-term responders [LTRs]). Best LTR responses consisted of 25 (71%) complete remissions and 10 (29%) partial remissions. In addition to clinical responses, an increase in IgA, IgG, and IgM levels of >50% from baseline was reported in 61%, 45%, and 42% of LTRs. Normalization in the percentage of CD4+ and CD8+ cells and T-cell numbers was observed in 48%, 71% and 99% of LTRs. Compared with other patients in the study, LTRs had lower baseline plasma levels of β-2-microglobulin, were more likely to have trisomy 12, and less likely to have deletion 17p.
我们评估了 60 例接受来那度胺初始治疗的慢性淋巴细胞白血病患者的长期预后。中位随访 4 年后，尚未达到治疗失败时间，总生存率为 82%。35 例（58%）患者的缓解持续时间>36 个月（长期缓解者[LTR]）。最佳 LTR 缓解包括 25 例（71%）完全缓解和 10 例（29%）部分缓解。除了临床反应外，61%、45%和 42%的 LTR 报告 IgA、IgG 和 IgM 水平从基线升高>50%。48%、71%和 99%的 LTR 观察到 CD4+和 CD8+细胞百分比和 T 细胞数量的正常化。与研究中的其他患者相比，LTR 患者的基线血浆β-2-微球蛋白水平较低，更有可能出现 12 三体，而缺失 17p 的可能性较低。
